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ow  to  make  Mathematics  Biology’s  next  and  better  microscopeAn essay published in 2004 has the perceptive heading: “Math-
matics Is Biology’s Next Microscope, Only Better; Biology Is
athematics’ Next Physics, Only Better” [1]. This title neatly sum-
arises the developmental path taken by biology over the past 30
ears or so. It emphasises both the exciting role that mathematics
nd statistics are adopting in the identiﬁcation and quantiﬁcation
f wholly unimagined and entirely new realms within biology as
ell as the repercussions biology is precipitating in the prompting
f new developments in mathematics and statistics. The title also
nderlines the intensifying interlinking of numerous disciplines:
he complexity of biological and clinical phenomena requires
ncreasingly sophisticated, specialised and discipline-transcending
xpertise to complete a technical workﬂow comprising experimen-
al design, generation and analysis of data, interpretation of results
nd subsequent transparent reporting (Fig. 1).
Natural systems are highly complex and challenging to model,
s variables are frequently random, volatile and even contradictory.
ence the drive to constrain parameters by developing simpliﬁed
odel systems such as organotypic or tissue cultures that are less
omplex but more deﬁned and so can be more easily controlled.
uch systems are of course still highly intricate, and so invite fur-
her reductionism in the shape of engineered systems that include
 few components in a test tube and eventually result in mathemat-
cal modelling, which provides ultimate control but may  no longer
eﬂect the complexity under initial investigation.
ig. 1. Interpretation and publication of quantitative results requires interaction between a
etween the disciplines and every stage of the experimental process is beneﬁting from cr
ttp://dx.doi.org/10.1016/j.bdq.2014.09.001
214-7535 © 2014 Published by Elsevier GmbH. Open access under CC BY-NC-ND licenseFor many years, biological data were descriptive and even
the introduction of cell and molecular biology techniques did
not have an impact on the publication of data that were small-
scale, descriptive and univariate. Results were often referred to
as “semiquantitative” and whilst having the appearance of being
quantitative, they usually were based on highly variable, subjec-
tive interpretations of data images. The analysis of RNA by northern
blotting, of proteins by western blotting or the comparison of mRNA
levels by reverse transcription-PCR and subsequent gel analysis
readily come to mind. However, the development of increasingly
sensitive, speciﬁc and high throughput techniques such as real-
time quantitative PCR (qPCR), microarrays, digital PCR (dPCR), next
generation sequencing (NGS) and mass spectrometry has led to
their use in a wide variety of applications in a broad range of biolog-
ical and clinical subjects. This continuous expansion of molecular
technologies has swiftly resulted in a demand for more rigorous
quantiﬁcation of nucleic acids, proteins and small molecules in,
for example, molecular diagnostics [2]. However, compared with
a qualitative yes/no result, reliable, reproducible and biologically
relevant quantiﬁcation poses signiﬁcant problems in terms of sam-
ple preparation and quality control, assay design, optimisation and wide range of scientiﬁc disciplines. The diagram does not imply a linear relationship
oss-discipline interaction.
validation, collection of data, their analysis and, importantly, pru-
dent and transparent reporting [3].
Quantitative experiments investigating physiology frequently
involve the investigation of individual cellular processes either by
.
A n and
s
s
m
p
m
m
c
d
s
i
a
a
i
a
c
c
e
p
s
r
c
o
b
t
e
t
T
t
p
c
p
r
s
a
b
m
f
m
a
l
t
c
w
[
w
r
r
s
n
M
i
a
g
t
e
w
a
m
b
t
s
d
[
[
[
[
[
[
[
[
[
[
[20] Bustin SA. Why  the need for qPCR publication guidelines? The case for MIQE.
Methods 2010;50:217–26.2 Editorial / Biomolecular Detectio
tudying the dynamic interplay of distinct cell types in various tis-
ues or analysing a small number of single cells. In either case, error
ay be introduced, and this must be both captured and, where
ossible, reduced using appropriate experimental design and nor-
alisation strategies. Ultimately, the generation of quantitative
ultivariate measurements enables the application of statisti-
al tests and correlation analyses that allow scientists to report
etailed information about their own experiments in a more pre-
cribed and systematised manner.
Systems biology generates prodigious amounts of complex,
ntegrated data from the ﬁelds of functional genomics, proteomics
nd metabolomics and has started to emerge as a driving force
t the interface of biology, biochemistry, mathematics, comput-
ng engineering, and physics [4]. It has become accepted, albeit
lso widely ignored, that the complexity of a biological organism
annot be described by a static listing of even the most well-
haracterised components such as DNA sequence, genetic and
pigenetic modiﬁcations, levels of coding and noncoding RNAs,
roteins and their many isoforms or the range of metabolites being
ynthesised or entering individual cells. Instead, it is the tempo-
al, special and dynamic arrays of interactions of each one of these
onstituents that determines cell responses and, ultimately, an
rganism’s behaviour. Consequently, an understanding of complex
iological systems requires the extensive support of computational
ools [5] together with agreed standards to enhance information
xchange, results compatibility and mutual understanding [6–8].
There  are numerous issues relating to the entire quantiﬁca-
ion workﬂow that are difﬁcult to standardise and automate.
hese include variables such as the wide variety of sample
ypes that can be tested, the complex steps involved in sample
reparation and, not least, a frequent switch to novel techni-
al platforms leading to inconsistent results as well as complex
ost-testing analysis methods [9]. Sample preparation affects the
eliability of PCR [10], the sensitivity and robustness of mass
pectrometric analysis [11] and the accuracy of protein-DNA inter-
ctions mapped using chromatin immunoprecipitation followed
y high-throughput sequencing (ChIP-seq) [12]. Similarly, ELISA
easurements can be compromised by technical issues [13], inter-
ering endogenous and exogenous effects [14] or measurement
ethodology [15], with signiﬁcant consequences for diagnosis
nd or clinical decision-making. One consequence of these chal-
enges is many omics assays are insufﬁciently sensitive or speciﬁc
o meet clinical needs [16]. Worse, most biomedical research
annot be independently replicated [17], a ﬁnding consistent
ith an estimate that around 85% of research funding is wasted
18].
The need for more rigour has been recognised for a long time,
ith detailed discussions published regarding the reliability of
esults obtained from qPCR [19,20], dPCR [21–23] or microar-
ay analyses [24,25]. These have resulted in a range of proposed
olutions aimed at improving the quantitative nature of such tech-
ologies, for example recommendations such as the MIAME  [26],
IQE [27,28] and dPCR MIQE [29] guidelines. Unfortunately there
s a wide disregard for these recommendations, an attitude char-
cterised by one “scientist’s” comment that compliance with PCR
uidelines was being “too dogmatic”. It has also become apparent
hat unless proper guidance is accorded to NGS [30–33], this pow-
rful technique will join all the others and also go powerfully wrong
hen not appropriately used or reported.
Discussion of the many methods in use today, as well as their
dvantages and disadvantages needs to be coupled to improve-
ents and innovations that can only arise from the interplay
etween different expertise, ideas and communication. These must
hrive in a milieu that adapts the scientiﬁc rigour of mathematics,
tatistics, chemistry and physics whilst retaining the versatile and
ynamic characteristics of biological scientists.
[
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Biomolecular  Detection and Quantiﬁcation (BDQ) is an open
access, peer-reviewed international journal dedicated to champi-
oning excellence in molecular study design, measurement, data
analysis and reporting. Its focus is on the application of qualitative
and quantitative molecular methodologies to all areas of clinical
and life sciences. The journal has two  main aims:
• to  provide a forum for discussion and recommendation of
guidelines  designed to improve the accuracy of molecular mea-
surement,  its data analysis and the transparency of its subsequent
reporting;
• to  publish molecular biology based studies that adhere to best
practice  guidelines, both current and future.
The  deliberately broad scope of the journal covers clinical areas
such as cancer, epigenetics, metagenomics, and infectious diseases
as well non clinical subjects including environmental, microbiol-
ogy and food science. BDQ revolves around the common theme of
promoting excellence in molecular measurement and its data anal-
ysis. It will serve as a repository for sharing key ﬁndings across what
may  otherwise be disparate specialties.
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